“This fluctuation was 40 primarily due to increased interest expense as a result of the Term B Loan that was entered into in March 2025 and the inclusion of interest income on customer deposits in revenue in the three months ended March 31, 2026 rather than in interest income in the three months ended March 31, 2025.”
“37 Table of contents Research and Development R&D expense increased $14.5 million, or 13%, during the nine months ended September 30, 2025, as compared to the same period in 2024, primarily due to higher personnel and related expenses.”
“Restructuring, other exit costs, and facility reductions 30 (75) (71) % 105 The decrease is due to the restructuring plan initiated during the first quarter of fiscal 2026 which was substantially complete as of January 31, 2026.”